Journal
JOURNAL OF IMMUNOLOGY
Volume 203, Issue 5, Pages 1105-1110Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1900594
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R01CA188419, P01-CA186866, F31CA217010]
- Translational Science Laboratory, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]
- NIH/National Center for Advancing Translational Sciences Grants [TL1 TR001451, UL1 TR001450]
Ask authors/readers for more resources
Aside from their roles in hemostasis and thrombosis, thrombocytes or platelets also promote tumor growth via immune suppression. However, the extent to which platelet activation shapes the immunosuppressive tumor microenvironment (TME) and whether platelet inhibition can be leveraged to improve checkpoint blockade are unknown. We show in this study that platelet function in mice mediates suppression of CD8(+) T cell function within the TME but not in the draining lymph nodes. Tempering platelet activation genetically reduced TGF-beta signaling in both immune and nonimmune cells in the TME, enhanced T cell frequency and function, and decreased CD11b(+) myeloid cell infiltration in the tumor. Targeting platelet function pharmacologically in tumor-bearing mice with aspirin and clopidogrel in combination with PD-1 blockade improved tumor control. These results suggest that platelet function represents a continuous, supplemental mechanism of immune evasion co-opted by tumors to evade antitumor immunity and offers an attractive target for combination with immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available